Study summary

Dupilumab put most young children into tissue remission

Dupilumab in children trial · 102 children, phase 3 · Published June 2024, New England Journal of Medicine

68%in tissue remission on the higher dose, vs 3% with placebo

What was tested

Dupilumab, an antibody blocking IL-4 and IL-13 signals, against placebo in children aged 1 to 11 with eosinophilic esophagitis.

What they found

Tissue remission occurred in 68% on the higher dose and 58% on the lower dose, vs 3% with placebo.

What it means

Led to FDA approval for children as young as 1 year (weighing at least 15 kg).

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.